Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus : A Post Hoc Analysis
(2016) In Diabetes Therapy 7(3). p.583-590- Abstract
Introduction: The extent to which postprandial glucagon reductions contribute to lowering of postprandial glucose in patients with type 2 diabetes mellitus (T2DM) is currently unknown. The aim of this analysis was to determine whether a reduction in postprandial glucagon following treatment with the glucagon-like peptide-1 receptor agonist lixisenatide correlates with a reduction in postprandial glucose and glycated hemoglobin (HbA1c) in patients with T2DM. Methods: A post hoc analysis was performed on pooled data from the modified intent-to-treat populations of two lixisenatide Phase 3 trials: GetGoal-M (lixisenatide versus placebo as add-on to metformin) and GetGoal-S (lixisenatide versus placebo as add-on to sulfonylurea... (More)
Introduction: The extent to which postprandial glucagon reductions contribute to lowering of postprandial glucose in patients with type 2 diabetes mellitus (T2DM) is currently unknown. The aim of this analysis was to determine whether a reduction in postprandial glucagon following treatment with the glucagon-like peptide-1 receptor agonist lixisenatide correlates with a reduction in postprandial glucose and glycated hemoglobin (HbA1c) in patients with T2DM. Methods: A post hoc analysis was performed on pooled data from the modified intent-to-treat populations of two lixisenatide Phase 3 trials: GetGoal-M (lixisenatide versus placebo as add-on to metformin) and GetGoal-S (lixisenatide versus placebo as add-on to sulfonylurea [SU] ± metformin). Glucagon levels were assessed 2 h after a standardized meal test performed at baseline and Week 24 and were examined for correlation with changes in 2-h postprandial glucose and HbA1c. Results: Lixisenatide reduced 2-h postprandial glucagon at Week 24 compared with placebo (P < 0.00001). The mean change in postprandial glucagon significantly correlated with reductions in postprandial glucose (P < 0.00001) and HbA1c (P < 0.00001). Conclusion: A reduction in postprandial glucagon following lixisenatide administration correlated with a decrease in postprandial glucose and HbA1c in patients with T2DM insufficiently controlled on metformin and/or SU. This suggests that lowering of postprandial glucagon contributes to the overall glycemic improvement observed with lixisenatide. Funding: Sanofi. Clinical Trial Numbers: NCT00712673 (GetGoal-M) and NCT00713830 (GetGoal-S).
(Less)
- author
- Ahrén, Bo LU ; Galstyan, Gagik ; Gautier, Jean Francois ; Giorgino, Francesco ; Gomez-Peralta, Fernando ; Krebs, Michael ; Nikonova, Elena ; Stager, William and Vargas-Uricoechea, Hernando
- organization
- publishing date
- 2016-09-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Glucagon, Glucagon-like peptide-1 receptor agonist, Glycemic control, Lixisenatide, Prandial, Type 2 diabetes mellitus
- in
- Diabetes Therapy
- volume
- 7
- issue
- 3
- pages
- 8 pages
- publisher
- Springer
- external identifiers
-
- scopus:84986201026
- pmid:27319011
- wos:000382882000017
- ISSN
- 1869-6953
- DOI
- 10.1007/s13300-016-0179-6
- language
- English
- LU publication?
- yes
- id
- 991ff9cc-bb35-467e-96e0-a9d6601c78f7
- date added to LUP
- 2016-12-13 11:20:00
- date last changed
- 2024-01-04 18:54:31
@article{991ff9cc-bb35-467e-96e0-a9d6601c78f7,
abstract = {{<p>Introduction: The extent to which postprandial glucagon reductions contribute to lowering of postprandial glucose in patients with type 2 diabetes mellitus (T2DM) is currently unknown. The aim of this analysis was to determine whether a reduction in postprandial glucagon following treatment with the glucagon-like peptide-1 receptor agonist lixisenatide correlates with a reduction in postprandial glucose and glycated hemoglobin (HbA<sub>1c</sub>) in patients with T2DM. Methods: A post hoc analysis was performed on pooled data from the modified intent-to-treat populations of two lixisenatide Phase 3 trials: GetGoal-M (lixisenatide versus placebo as add-on to metformin) and GetGoal-S (lixisenatide versus placebo as add-on to sulfonylurea [SU] ± metformin). Glucagon levels were assessed 2 h after a standardized meal test performed at baseline and Week 24 and were examined for correlation with changes in 2-h postprandial glucose and HbA<sub>1c</sub>. Results: Lixisenatide reduced 2-h postprandial glucagon at Week 24 compared with placebo (P < 0.00001). The mean change in postprandial glucagon significantly correlated with reductions in postprandial glucose (P < 0.00001) and HbA<sub>1c</sub> (P < 0.00001). Conclusion: A reduction in postprandial glucagon following lixisenatide administration correlated with a decrease in postprandial glucose and HbA<sub>1c</sub> in patients with T2DM insufficiently controlled on metformin and/or SU. This suggests that lowering of postprandial glucagon contributes to the overall glycemic improvement observed with lixisenatide. Funding: Sanofi. Clinical Trial Numbers: NCT00712673 (GetGoal-M) and NCT00713830 (GetGoal-S).</p>}},
author = {{Ahrén, Bo and Galstyan, Gagik and Gautier, Jean Francois and Giorgino, Francesco and Gomez-Peralta, Fernando and Krebs, Michael and Nikonova, Elena and Stager, William and Vargas-Uricoechea, Hernando}},
issn = {{1869-6953}},
keywords = {{Glucagon; Glucagon-like peptide-1 receptor agonist; Glycemic control; Lixisenatide; Prandial; Type 2 diabetes mellitus}},
language = {{eng}},
month = {{09}},
number = {{3}},
pages = {{583--590}},
publisher = {{Springer}},
series = {{Diabetes Therapy}},
title = {{Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus : A Post Hoc Analysis}},
url = {{http://dx.doi.org/10.1007/s13300-016-0179-6}},
doi = {{10.1007/s13300-016-0179-6}},
volume = {{7}},
year = {{2016}},
}